Tonix Pharmaceuticals Holding Corp.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — |
| Operating income | -$125.7M | -$136.7M | -$118.4M | -$112.1M | -$92.3M |
| Cost of revenue | $6.6M | $7.8M | $4.7M | — | — |
| Cash from operations | -$99.8M | -$60.9M | -$102.0M | -$98.1M | -$75.6M |
| Capital expenditure | $3.4M | $120,000 | $7.9M | $48.1M | $35.3M |
| Free cash flow | -$103.2M | -$61.0M | -$109.9M | -$146.2M | -$110.9M |
| Share repurchases | $13.8M | — | $14.0M | — | — |
| Impairments | — | $59.0M | — | — | — |
| Total assets | $277.2M | $162.9M | $154.5M | $225.7M | $240.9M |
| Total liabilities | $32.0M | $23.3M | $48.9M | $18.5M | $22.2M |
| Total debt | — | $5.8M | $8.7M | — | — |
Shares outstanding 15.9M · Free float 94.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.